The efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac vaccines in patients with cancer.

Simsek, Melih; Yasin, Ayse I; Besiroglu, Mehmet; Topcu, Atakan; Sucuoglu Isleyen, Zehra; Seker, Mesut; Turk, Haci Mehmet

Simsek, Melih; Yasin, Ayse I; Besiroglu, Mehmet; Topcu, Atakan; Sucuoglu Isleyen, Zehra; Seker, Mesut; Turk, Haci Mehmet.

Afiliação

Simsek M; Departments of Medical Oncology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.
Yasin AI; Departments of Medical Oncology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.
Besiroglu M; Departments of Medical Oncology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.
Topcu A; Departments of Medical Oncology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.
Sucuoglu Isleyen Z; Departments of Medical Oncology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.
Seker M; Departments of Medical Oncology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.
Turk HM; Departments of Medical Oncology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.

J Med Virol ; 94(9): 4138-4143, 2022 09.

Article em En | MEDLINE | ID: mdl-35513241

Assuntos

COVID-19; Neoplasias; Vacinas; Vacina BNT162; COVID-19/prevenção & controle; Vacinas contra COVID-19; Estudos Transversais; Humanos; Neoplasias/complicações; Estudos Retrospectivos

Palavras-chave

COVID-19; SARS-CoV-2; cancer; vaccination

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Vacinas / COVID-19 / Neoplasias Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Med Virol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Turquia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google